Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

SYSTEMATIC REVIEW AND META-ANALYSIS OF THE USE OF ANTIFIBRINOLYTIC AGENTS IN TOTAL KNEE REPLACEMENT (SMAK)



Abstract

Since the era of total knee replacement (TKR) began in the late 1960s, total knee replacement has become one of the commonest operations in orthopaedic practice.

TKR is frequently associated with transfusion of allogenic blood Benoni G 1995; Seppo T 1997. In our centre, 30 % of patients who had undergone TKR received allogenc blood transfusion perioperatively. Although, serological screening has reduced the risk for viral infection to a very low levelKlein HG 1995; Schreiber GB 1996, the public is still concerned about this potential serious complication. Allogenic blood transfusion can be also associated with other non infectious complications such as haemolysis, immunosuppression, transfusion-related acute lung injury and even death.Madjdpour C 2005 Therefore, further refinement of strategies to avoid exposure to allogeneic blood is needed.

Amongst the technologies to minimise the need for blood transfusion is the use of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon amino-caproic acid (EACA).New Reference

Objectives: The purpose of this review is to investigate the evidence for the efficacy of Tranexamic acid in reducing peri-operative blood loss and blood transfusion after total knee replacement, and the evidence for any effect on clinical outcomes such as reduction in re-operation rates or increase in complication rates (e.g. deep venous thrombosis, pulmonary embolism, ischaemic heart diseases and mortality).

Method: Systematic review and metananalysis based on Cochrane guidelines of all randomised and quasirandomised trials.

Results: Fiften RCTs were included in the study; there has been a significant reduction of blood loss (P value 0.00001, I2 = 89%), blood transfusion without increase in systeanatic side effects such as ischaemic heart diseases, DVT, pulmondary embolisms. There was no singnificant difference in length of stay.

Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Email: office@efort.org